![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, June 17, 2016 5:12:07 PM
Source: Edgar (US Regulatory)
FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person *
MCENANY PATRICK J 2. Issuer Name and Ticker or Trading Symbol
CATALYST PHARMACEUTICALS, INC. [ CPRX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__ X __ Director _____ 10% Owner
__ X __ Officer (give title below) _____ Other (specify below)
President and CEO
(Last) (First) (Middle)
355 ALHAMBRA CIRCLE, SUITE 1250 3. Date of Earliest Transaction (MM/DD/YYYY)
6/15/2016
(Street)
CORAL GABLES, FL 33134
(City) (State) (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options to purchase common stock $0.79 6/15/2016 A 100000 6/15/2017 6/15/2023 Common Stock 100000 $0 1000000 D
Options to purchase common stock $0.79 6/15/2016 A 100000 6/15/2018 6/15/2023 Common Stock 100000 $0 1100000 D
Explanation of Responses:
Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
MCENANY PATRICK J
355 ALHAMBRA CIRCLE, SUITE 1250
CORAL GABLES, FL 33134 X
President and CEO
Signatures
/s/ Patrick J. McEnany 6/17/2016
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Recent CPRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 09:00:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/07/2024 03:17:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 09:00:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 09:00:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 02:41:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 04:22:56 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/31/2024 08:50:35 PM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 05/31/2024 08:47:26 PM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 05/31/2024 08:46:49 PM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 05/31/2024 08:43:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:43:02 PM
- Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE® • GlobeNewswire Inc. • 05/30/2024 05:41:21 PM
- Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024 • GlobeNewswire Inc. • 05/28/2024 12:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 09:28:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:54:04 PM
- Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/08/2024 08:16:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:06:47 PM
- Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024 • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day • GlobeNewswire Inc. • 03/28/2024 12:03:00 PM
- Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium • GlobeNewswire Inc. • 03/27/2024 12:03:00 PM
- Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) • GlobeNewswire Inc. • 03/13/2024 11:55:00 AM
- Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference • GlobeNewswire Inc. • 03/05/2024 01:03:00 PM
- Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/28/2024 11:03:23 PM
- Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE • GlobeNewswire Inc. • 02/27/2024 01:03:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM